Summary.-m-AMSA is an intercalating agent at present on Phase II trial as a chemotherapeutic drug. A 30min exposure of Chinese hamster (Line V79-753B) cells to submicromolar concentrations of m-AMSA killed 50%O of the cells. The survivors had an enhanced sensitivity to radiation-induced cell killing. Depending upon the conditions, m-AMSA enhanced the radiation effect by either a decrease in the survival-curve shoulder or by an increase in slope. m-AMSA may act partly by suppressing the accumulation of sublethal damage but, if so, recovery from damage as measured in split-dose experiments with cells pretreated with the drug is not affected. m-AMSA increased radiation lethality throughout the cell cycle, but a contribution to its radiation effect from selective toxicity to cells in a radioresistant phase of the cell cycle cannot be excluded. Radiation and the drug interacted to give increased cell killing, even when the exposures to each agent were separated in time.
had an enhanced sensitivity to radiation-induced cell killing. Depending upon the conditions, m-AMSA enhanced the radiation effect by either a decrease in the survival-curve shoulder or by an increase in slope. m-AMSA may act partly by suppressing the accumulation of sublethal damage but, if so, recovery from damage as measured in split-dose experiments with cells pretreated with the drug is not affected. m-AMSA increased radiation lethality throughout the cell cycle, but a contribution to its radiation effect from selective toxicity to cells in a radioresistant phase of the cell cycle cannot be excluded. Radiation and the drug interacted to give increased cell killing, even when the exposures to each agent were separated in time.
It is concluded that m-ASMA may behave like actinomycin D and adriamycin, and enhance clinical radiation responses. In vivo testing to determine the effect of m-AMSA on the therapeutic index is recommended.
AMONG THE NEW CYTOTOXIC AGENTS
that therapists hope will extend the range of cancer chemotherapeutic drugs are the 9-anilinoacridines developed by Cain and his co-workers (Denny et al., 1978 , and references therein). Reversibility of myelosuppression and limited other side effects are attractive features of m-AMSA (4'-[9 -acridinylamino] -methanesulphon -manisidide) the derivative on which attention has been focused initially. m-AMSA is now on Phase II trial in the U.S.A. and Europe, and the encouraging preclinical and Phase I data have been reviewed (Rozeneweig et al., 1979) . Although the mechanism of action of the drug is uncertain, it is probable that its ability to bind to DNA by intercalation (Waring, 1976 ) is involved. Tobey et al. (1978) have shown that mammalian cells in vitro have a similar response to m-AMSA and to Adriamycin (ADR), another intercalating agent. This has caused the 9-anilinoacridines to be placed in the category of cytotoxic intercalating agents such as ADR and actinomycin D (AMD).
Many cytotoxic drugs have effects that are non-interactive with the cell-killing effects of radiation, while others actually enhance the ability of radiation to kill cells. This is one reason for the current interest in combined chemotherapyradiotherapy treatments. Intercalating agents such as ADR and AMD are notable in that enhancement has been observed in many tissues, both normal and malignant (Phillips & Fu, 1979) . These drugs also display the "recall" phenomenon whereby enhancement of damage occurs even when the drug and radiation exposures are widely separated in time (D'Angio, 1962; Donaldson et al., 1974) . It is of obvious importance to establish whether m-AMSA interacts with radiation damage under clinical conditions, and to investigate whether any interaction is likely to be therapeutically useful or disadvantageous. As a first step the interaction has been studied in vitro. An earlier paper showed that the drug sensitized irradiated bacterial cells by removing the shoulder on the survival curve (Roberts et al., 1979) . Here we report the results with mammalian cells.
METHODS
in-AMSA was kindly supplied by Dr B. F. Cain and made up in distilled water just before use. Concentrations were measured spectrophotometrically at 433 nm (E =1120 m2/mol) and then diluted into medium or Dulbecco's phosphate-buffered saline "A" (PBSA) as required. The drug had a half-life in PBSA and in medium of at least 10 h, as judged by the retention of optical absorbance and drug toxicity.
Chinese hamster cells, Line V79-753B, were maintained as asynchronous exponential cultures in 4oz medical flats in Earle's minimal essential medium supplemented with, 15% foetal calf serum and 14 mm HEPES buffer as described previously (Cooke et al., 1976) . For experiments, cells were harvested, resuspended in fresh growth medium and plated on to 60mm glass Petri dishes (2 x 102 to 104 cells/dish) in a total volume of 2 ml of growth medium. When the cells had attached to the glass, the medium was aspirated from the dishes and replaced with 2 ml of fresh growth medium or PBSA with or without m-AMSA as appropriate. Triplicate dishes were placed in "Dural" containers, gassed with "white spot" N2 for 1 h if 02 was to be removed, and sealed before irradiation.
Irradiations were carried out using a 60Co source and a dose rate of about 4 Gy/min. Unless otherwise indicated, the cultures were replenished after irradiation with 2 ml of fresh growth medium and incubated for 7 days at 37°C in an atmosphere of 5% CO2-95% air to permit colony formation. The medium was then removed from the dishes, and the colonies were fixed with ethanol, stained with methylene blue and counted.
For experiments involving synchronized cells, 1 25mM hydroxyurea in full growth medium was added to cells which had been plated on to dishes 16 h previously and incubated at 37°C. After 5 h the hydroxyurea was replaced with fresh drug-free medium and the surviving cells proceeded through the cycle from the G1-S boundary.
All experiments were done at least twice, and in survival-curve experiments the pooled data were analysed by regression analysis to the multi-target equation using a CDC 400 computer (Millar et al., 1978) . The parameters from the regression analysis were subjected to a minimizing subroutine to obtain values for Do, n, Dq and errors (Powell, 1971) .
These values were used in a second programme (J. L. Millar, unpublished) to give theoretical curves from the computed data. Data were analysed in this way to remove subjective bias. It is not intended that the multi-target equation used should be the best possible fit of the data (see Millar et al., 1978) .
Technical difficulties found in experiments with other intercalating agents have included the binding of these drugs to plastic or glass Petri dishes, and the slow release of the drugs from killed cells. Similar problems were not encountered with m-AMSA under our conditions, but to minimize any possible toxic effect due to the slow release of drug, the maximum number of cells plated per dish was 104.
RESULTS AND DISCUSSION
Survival curves for asynchronous cells Investigations of the interaction between radiation and m-AMSA are restricted to submicromolar drug concentrations since, as Fig. 1 shows, m-AMSA is highly toxic to mammalian cells. The curves in Fig. 1 are similar to those for ADR (Byfield et al., 1977; 1977). In view of the toxicity of m-AMSA, when cells were irradiated in combination with the drug the surviving fractions were calculated by normalizing the observed survivors to the number of survivors in unirradiated cultures that had been exposed to the drug for a similar length of time. This allowed cytotoxicity and the radiation response of drug-treated cells to be separated. The m-AMSA treatment used most (Table) , in contrast to cells surviving 0-2 ELM.
When cells were exposed for 30 min to m-AMSA at room temperature in full growth medium, the toxicity was less than in cells exposed to similar drug concentrations in PBSA. The radiation killing of cells that had been exposed to 0-2juM m-AMSA in full growth medium was enhanced, with a decrease in all 3 parameters n, Dq and Do (Table) . When cells were irradiated after a 30min exposure to 0-35[M m-AMSA, a drug concentration in medium that produced similar toxicity to that in cells exposed to 02[kM of the drug in PBSA, the decrease in cell survival was mainly due to a change in D,. The Table   also shows that m-AMSA increased radiation-induced cell killing under hypoxic conditions. Reductions in n, Dq and Do were found after drug treatment. Apparently m-AMSA can interact with radiation damage in both aerobic and hypoxic cells, giving similar increases in cell killing. Tissue hypoxia per se is unlikely to protect irradiated tissues or tumours against enhancement by m-AMSA, nor will it be the basis of a differential gain in tumours.
In summary, a drug concentration that is moderately toxic in PBSA reduces the size of the shoulder, but at higher concentrations, or in full growth medium or in hypoxia, changes in Do are apparent. The ability of the experimental conditions to determine whether changes in n or Do describe the enhancement of radiation effects is not unique to m-AMSA. Other intercalating agents exhibiting similar behaviour are AMD (Elkind & Whitmore, 1967) , ADR (compare Belli & Piro, 1977 , with Byfield et al., 1977 and quinacrine (Saladino & Ben-Hur, 1978) .
Timing of the drgu and radiation treatments
The intercalating drugs AMD and ADR display a "recall" phenomenon, in which an enhanced clinical response is observed even when the drug and radiation treatments are separated in time (D'Angio, 1962; Donaldson et al., 1974) . In vitro, more than additive cell killing occurs with time-separated treatments (Belli & Piro, 1977; Piro et al., 1975) . Similarly, we have found that exposures to m-AMSA and radiation need not be simultaneous for an interaction to occur. Fig. 3 shows that cell killing was enhanced even if cells were maintained in drug-free PBSA at 37°C for a period between sequential treatments in which the drug exposure was followed some time later by 7.4 Gy or vice versa. Positive times refer to the interval between irradiation and a 30min exposure radiation remained fully effective for at least 2 h after the drug had been removed. Enhanced cell killing was also found when the drug followed the radiation, but only if the treatments were less than about 2 h apart. The time course for the loss of a post-irradiation interaction is similar to that found with AMD (Elkind et al., 1968) but it differs from the response found with ADR, for which an increased interaction was shown as the post-irradiation interval increased up to 2 h (Belli & Piro, 1977) . The loss ofinteraction found with m-AMSA given after irradiation could be due to recovery from sublethal radiation injury, as suggested by Elkind et al. (1968) for AMD (see next section).
The effect of mn-A MSA on Elkind-Sutton recovery Enhanced radiation killing of cells exposed to intercalating agents such as ADR, AMD and quinacrine has usually been apparent, at least in part, as a decrease in the shoulder of the cell-survival curve. The decrease has been attributed usually to a reduced ability to accumulate sublethal damage as a result of exposure to the drug (e.g. Elkind et al., 1967; Belli & Piro, 1977) . m-AMSA is an intercalating agent (Waring, 1976) and interferes with DNA synthesis and nucleic acid polymerases (Gormley et al., 1978) and a similar explanation may be reasonable for the results reported above. It was of interest to determine whether m-AMSA could suppress the recovery process that occurs when cells are incubated in medium at 37°C between two radiation doses (Elkind -Sutton recovery). Conditions were used that most clearly enhanced radiation effects via a decrease in the shoulder of the survival curve. Before the first radiation dose, cells were exposed to 021uM m-AMSA in PBSA at room temperature. After irradiation the drug was replaced with full growth medium and incubated at 370C for various times to allow for recovery, followed by a second radiation dose. Fig. 4 shows that there was no difference between cells pre- treated with m-AMSA and untreated control cells, either in the time course or in extent of recovery. Therefore, if m-AMSA pre-treatment does suppress the accumulation of sublethal damage, it does not interfere with Elkind-Sutton recovery. In this it resembles ADR (Belli & Piro, 1977) and differs from AMD (Elkind et al., 1964) . Whatever the actual mechanism, it should be noted that, for at least two intercalating drugs, an apparent decrease in the size of the initial shoulder is not directly linked to suppression of recovery between successive doses. Synchronised cells In this work m-AMSA enhanced radiation damage only under conditions that were also toxic to the cells. An alternative explanation for the action of m-AMSA could be that the drug alters the distribution of cells in the cell cycle, resulting in a cell population that is more radiationsensitive than a normal, asynchronous population. This could occur, for example, if the drug is particularly toxic to cells in late S, the most radioresistant phase of the cell cycle (Sinclair, 1968) . Evidence supporting such a mechanism has been found by Wilson & Whitmore (in preparation (Cysyk et al., 1977 Any therapeutic gain from the combination of radiotherapy and m-AMSA is likely to arise from differential uptake/retention in tumours and normal tissue. Such a differential has been suggested for melanotic tissues (Shoemaker et al., 1978) . Experiments are required to test whether m-AMSA interacts with radiation damage in vivo and to decide whether any interaction observed will cause a gain or loss in the therapeutic index.
